Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.

Stroh M, Palcza J, McCrea J, Marsilio S, Breidinger S, Panebianco D, Johnson-Levonas A, Kraft WK, Orford K, Murphy G, Agrawal N, Trucksis M, Wagner JA, Iwamoto M.

Cancer Chemother Pharmacol. 2012 May;69(5):1247-53. doi: 10.1007/s00280-011-1819-1.

PMID:
22290273
2.

Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.

Johnson BM, Adams LM, Zhang K, Gainer SD, Kirby LC, Blum RA, Apseloff G, Morrison RA, Schutz RA, Lebowitz PF.

J Clin Pharmacol. 2010 Aug;50(8):951-9. doi: 10.1177/0091270009353761. Epub 2010 Feb 2.

PMID:
20124517
3.

Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.

Sarantopoulos J, Mita AC, Wade JL, Morris JC, Rixe O, Mita MM, Dedieu JF, Wack C, Kassalow L, Lockhart AC.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1113-24. doi: 10.1007/s00280-014-2572-z. Epub 2014 Oct 12.

PMID:
25307552
4.

The minimal impact of food on the pharmacokinetics of ridaforolimus.

Stroh M, Li X, Marsilio S, Panebianco D, Johnson-Levonas A, Juan A, Orford K, Agrawal N, Trucksis M, Wagner JA, Murphy G, Iwamoto M.

Cancer Chemother Pharmacol. 2012 Jul;70(1):177-82. doi: 10.1007/s00280-012-1897-8. Epub 2012 Jun 6.

PMID:
22669570
5.

Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmation.

Stroh M, Talaty J, Sandhu P, McCrea J, Patnaik A, Tolcher A, Palcza J, Orford K, Breidinger S, Narasimhan N, Panebianco D, Lush R, Papadopoulos KP, Wagner JA, Trucksis M, Agrawal N.

J Clin Pharmacol. 2014 Nov;54(11):1256-62. doi: 10.1002/jcph.331. Epub 2014 May 24.

PMID:
24827931
6.

Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism.

Gandelman K, Zhu T, Fahmi OA, Glue P, Lian K, Obach RS, Damle B.

J Clin Pharmacol. 2011 Feb;51(2):229-36. doi: 10.1177/0091270010366445. Epub 2010 Apr 6.

PMID:
20371736
7.

Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants.

Tanaka C, Yin OQ, Smith T, Sethuraman V, Grouss K, Galitz L, Harrell R, Schran H.

J Clin Pharmacol. 2011 Jan;51(1):75-83. doi: 10.1177/0091270010367428. Epub 2010 Aug 11.

PMID:
20702754
8.

The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.

Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, McKeever EG Jr, Punwani NG, Williams WV, Yeleswaram S.

J Clin Pharmacol. 2012 Jun;52(6):809-18. doi: 10.1177/0091270011405663. Epub 2011 May 20.

PMID:
21602517
9.

The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers.

Garg V, Chandorkar G, Yang Y, Adda N, McNair L, Alves K, Smith F, van Heeswijk RP.

Br J Clin Pharmacol. 2013 Feb;75(2):431-9. doi: 10.1111/j.1365-2125.2012.04345.x.

10.

Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals.

Moody DE, Walsh SL, Rollins DE, Neff JA, Huang W.

Clin Pharmacol Ther. 2004 Aug;76(2):154-66.

PMID:
15289792
11.

The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.

Yee KL, Khalilieh SG, Sanchez RI, Liu R, Anderson MS, Manthos H, Judge T, Brejda J, Butterton JR.

Clin Drug Investig. 2017 Jul;37(7):659-667. doi: 10.1007/s40261-017-0513-4.

PMID:
28353169
12.

Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.

Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J.

Clin Drug Investig. 2013 Jun;33(6):429-40. doi: 10.1007/s40261-013-0084-y.

PMID:
23625188
13.

Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.

Ling SY, Huizinga RB, Mayo PR, Larouche R, Freitag DG, Aspeslet LJ, Foster RT.

Br J Clin Pharmacol. 2014 Jun;77(6):1039-50. doi: 10.1111/bcp.12309.

14.

Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations.

Yang Z, Vakkalagadda B, Shen G, Ahlers CM, Has T, Christopher LJ, Kurland JF, Roongta V, Masson E, Zhang S.

J Clin Pharmacol. 2013 Feb;53(2):217-27. doi: 10.1177/0091270012439208.

PMID:
23436267
15.

The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.

Xu H, O'Gorman M, Tan W, Brega N, Bello A.

Eur J Clin Pharmacol. 2015 Dec;71(12):1441-9. doi: 10.1007/s00228-015-1945-5. Epub 2015 Sep 18.

PMID:
26381275
16.

The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study.

Shin KH, Kim BH, Kim TE, Kim JW, Yi S, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS.

Clin Ther. 2009 Dec;31(12):3009-20. doi: 10.1016/j.clinthera.2009.12.012.

PMID:
20110038
17.

Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus.

Boni JP, Leister C, Burns J, Hug B.

Br J Cancer. 2008 Jun 3;98(11):1797-802. doi: 10.1038/sj.bjc.6604376. Epub 2008 May 6.

18.
19.

Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.

Laille E, Patel M, Jones SF, Burris HA 3rd, Infante J, Lemech C, Liu L, Arkenau HT.

J Clin Pharmacol. 2015 Dec;55(12):1378-85. doi: 10.1002/jcph.560. Epub 2015 Jul 29.

20.

The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar.

Kosoglou T, Statkevich P, Kumar B, Xuan F, Schiller JE, Johnson-Levonas AO, Young S, Cutler DL.

J Clin Pharmacol. 2013 May;53(5):540-9. doi: 10.1002/jcph.20. Epub 2013 Feb 20.

PMID:
23426761

Supplemental Content

Support Center